Industry News
Pharmaceutical Industry News
The drumbeat of news regarding…
The drumbeat of news regarding Asian pharma—and particularly China—continues to grow louder. At the American Society of Clinical Oncology (ASCO) meeting, Akeso took center stage with an ivonescimab presentation, and Fierce’s Angus Liu took a
The platform was built in…
The platform was built in collaboration with Vertex Pharmaceuticals, a biopharma company that launched a non-opioid pain reliever in early 2025.
Three times as many deaths in the…
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since
The company inked another…
The company inked another settlement with a prospective generic maker, leaving no further pending patent litigation for its Sunosi on the table.
Medical device distribution giant…
Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of toxic bacteria in
In response to a planned…
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least
As its ultra-rare disease med…
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pick disease type C into one resembling
Cencora and Gilead have expanded…
Cencora and Gilead have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to the CAR-T cancer therapies Yescarta and Tecartus.
There were 487 booths at the…
There were 487 booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see them all.
The words used to describe disease…
The words used to describe disease can shape how patients are diagnosed, treated and understood. From mpox to obesity to the Fitzpatrick scale, outdated or imprecise language can deepen stigma and obscure the full scope
The FDA has hit QOL Medical with…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug.
As Neurotech Pharmaceuticals looks…
As Neurotech Pharmaceuticals looks to ramp up the launch of its first-ever commercial product, the biopharma is running a new video series to help boost awareness.
In 2017, a little-known company…
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly
The drugmaker has issued a June 8…
The drugmaker has issued a June 8 ultimatum to an unspecified number of hospitals that have resisted a data submission policy it implemented in February. Furious hospital industry groups are pushing back, calling the decision
A nonprofit has launched to change…
A nonprofit has launched to change how endometriosis is researched, treated and understood, starting with a documentary that features the stories of people including, Amy Schumer and Marilyn Monroe.
A Merck spokesperson attributed…
A Merck spokesperson attributed the layoffs to "the next phase of personnel impacts related to its multiyear optimization," which was unveiled last July.
A phase 3 study of Gilead’s…
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing that after 52 weeks it can normalize a key marker of disease progression for those with the liver disorder primary biliary cholangitis.
French drugmaker Sanofi is…
French drugmaker Sanofi is launching an AI agent to support its field reps as life sciences companies continue to ramp up their use of next-generation technology across their businesses.
As governments and health…
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for
Cingulate will need to take a…
Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns.